Gennex Laboratories Limited

GENNEX6

INE509C01026

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 04:01:15 2024-05-27 am EDT			5-day change	1st Jan Change
18.99 ^INR	+0.64%		+5.56%	+13.03%

Feb. 14	Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
Feb. 14	Gennex Laboratories Limited Appoints Dr. S. Ch. Dharma Rao as Additional Director (Non- Executive - Non Independent Director)	CI

Gennex Laboratories Limited agreed to acquire additional 6.73% minority stake in Deccan Remedies Limited.

December 23, 2021

Gennex Laboratories Limited (BSE:531739) intends to acquire additional 6.73% minority stake in Deccan Remedies Limited on December 24, 2021. Post acquisition, will hold 51% stake in Deccan Remedies Limited. Gennex Laboratories Limited (BSE:531739) agreed to acquire additional 6.73% minority stake in Deccan Remedies Limited on January 4, 2021.

Latest news about Gennex Laboratories Limited

Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
Gennex Laboratories Limited Appoints Dr. S. Ch. Dharma Rao as Additional Director (Non- Executive - Non Independent Director)	Feb. 14	CI
Gennex Laboratories Limited Announces Resignation of Tiruvarur Muralidharan Gopalakrishnan as Whole Time Director	Feb. 01	CI
Gennex Laboratories Gets Good Manufacturing Practices Certificate from Indian Regulator	Dec. 13	MT
Gennex Laboratories Limited announced that it expects to receive INR 966.125 million in funding from Premier Fiscal Services Pvt Ltd	Dec. 01	CI
Gennex Laboratories Board to Consider Raising Funds Via Equity	Nov. 29	MT
Gennex Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
Gennex Laboratories Gets Permission to Manufacture, Sell Fexofenadine, Minoxidil	23-08-10	MT
Gennex Laboratories Limited Obtains Approval of Additional Products from Drug Control Administration, Government of Telangana	23-08-09	CI
Gennex Laboratories Gets WHO-GMP Certification from Drug Control Administration, Government of Telangana	23-07-11	MT
Gennex Laboratories Arm Gets Drug Manufacturing License	23-06-01	MT
Gennex Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-31	CI
Gennex Laboratories Limited Appoints Dinesh Kumar Kejriwal as Company Secretary & Compliance Officer	23-04-20	CI
Gennex Laboratories Limited completed the acquisition of 6.73% minority stake in Deccan Remedies Limited.	23-02-28	CI
Gennex Laboratories Limited Approves the Acceptance of Resignation of Rajesh Vankadara as Company Secretary & Compliance Officer	23-02-14	CI
Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Gennex Laboratories Limited Announces Rajesh Vankadara to Resign as Company Secretary & Compliance Officer Effect from February 26, 2023	23-02-07	CI
Gennex Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
Gennex Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-12	CI
Gennex Laboratories Limited Receives New 2 Licenses to Manufacture Drugs for Purposes of Examination, Test or Analysis from the Drug Control Administration , Government of Telangana	22-07-27	CI
Gennex Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-30	CI
Gennex Laboratories Board OKs Up to $5.3 Million Rights Issue	22-04-06	MT
Gennex Laboratories Board to Consider Fundraising Via Debt or Equity Offering	22-03-28	MT
Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-14	CI
Gennex Laboratories Limited agreed to acquire additional 6.73% minority stake in Deccan Remedies Limited.	21-12-23	CI

Chart Gennex Laboratories Limited

Duration

Period

More charts

Company Profile

Gennex Laboratories Limited is an India-based active pharmaceutical ingredient manufacturing company. The Company is engaged in the business of manufacturing bulk drugs, intermediaries, and biotech products. The Company has a robust product portfolio spread over major product segments encompassing expectorants, muscle relaxants, analgesic and anti-fungal. The Company operates through the Pharmaceutical Products (Bulk Drugs) segment. The Company's products include active pharmaceutical ingredients, such as Guaifenesin USP/BP/EP/IP, which is an expectorant, (mucolyte); Methocarbamol USP, which is a relaxant (skeletal muscle relaxant); Phenazopyridine Hcl USP, which is an urinary tract analgesic; Fluconazole EP/USP, which is an anti-fungal product; Mephenesin IP/BP, which is a muscle relaxant; Chlorphenesin IP/BP, which is anti-fungal, and Melitracen Hcl, which is an antidepressant. The Company has manufacturing facilities in India which cater to both domestic and international markets.

Sector

Pharmaceuticals

Calendar

2024-05-29 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GENNEX LABORATORIES LIMITED	+13.03%	51.67M
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+32.79%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.15%	205B
ROCHE HOLDING AG	-5.81%	203B
AMGEN INC.	+6.19%	164B